Table 1 Adiponectin and markers of insulin resistance among the treatment groups (A), duration of therapy among the groups (B)

Age

34.5 (29.8; 41.0)

34.5 (31.3; 41.0)

35.5 (29.0; 41.0)

Years

0.986

BMI

27.7 (24.9; 30.4)

25.0 (23.8; 29.5)

25.7 (22.9; 29.7)

-

0.586

Waist

89 (82; 95)

83 (80; 93)

82 (76; 88)

cm

0.194

WHR

0.87 (0.82; 0.93)

0.85 (0.79; 0.89)

0.84 (0.80; 0.90)

-

0.315

Fasting insulin

5.5 (2.7; 10.1)

3.1 (2.1; 5.7)

4.4 (2.0; 8.0)

mIU/L

0.365

Fasting glucose

86 (81; 90)

91 (83; 98)

91 (85; 97)

mg/dL

0.145

2 hour glucose

104 (80; 113)

94 (85; 109)

94 (81; 109)

mg/dL

0.877

HOMA-IR

1.18 (0.54; 2.09)

0.72 (0.50; 1.17)

1.05 (0.41; 1.73)

-

0.479

QUICKI

0.37 (0.34; 0.42)

0.41 (0.37; 0.43)

0.38 (0.35; 0.45)

-

0.234

Total adiponectin

5.6 (3.4; 9.4)

7.3 (4.0; 8.7)

9.0 (7.6; 12.1)

ng/mL

0.039*

HMW adiponectin

2.2 (1.0; 3.9)

3.5 (1.8; 5.1)

5.3 (3.8; 7.0)

ng/mL

0.002*

HMW:Total adiponectin

0.35 (0.29; 0.42)

0.48 (0.41; 0.56)

0.56 (0.52; 0.61)

-

<0.0001**

(B) Duration of therapy among the treatment groups

Regimen 1

15 (8.5; 21.5)

12 (9.5; 20.0)

-

Months

Regimen 2

11.5 (9.3; 14.0)

-

-

Months

d4T

15.5 (9.8; 22.3)

10 (8; 17.5)

-

Months

AZT

9 (5; 16.5)

12 (11; 15.0)

-

Months